OrbiMed Leads $30M Round In Innovative Drug Developer Zai Lab

Healthcare-focused investment firm OrbiMed Asia Partners has led a US$30 million series C round in Zai Lab Ltd., a Shanghai-based innovative biopharmaceutical company.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets

LEAVE A REPLY